Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia
Phase 2
Completed
- Conditions
- B-CLL
- Registration Number
- NCT00162851
- Lead Sponsor
- Karolinska University Hospital
- Brief Summary
This is a Phase II trial to study the safety and tolerability of subcutaneous alemtuzumab administered without dose escalation to patients with advanced B-cell chronic lymphocytic leukemia (B-CLL).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- B-CLL that has failed fludarabine
Exclusion Criteria
- Performance status grade 3
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of subcutaneous alemtuzumab in B-CLL treatment?
How does subcutaneous alemtuzumab compare to intravenous administration in B-CLL trials?
What biomarkers predict response to alemtuzumab in B-cell chronic lymphocytic leukemia?
What are the key adverse events associated with subcutaneous alemtuzumab in B-CLL?
Are there combination therapies involving alemtuzumab for advanced B-cell CLL?
Trial Locations
- Locations (1)
Dept. of Hematology, Karolinska University Hospital
🇸🇪Stockholm, Sweden
Dept. of Hematology, Karolinska University Hospital🇸🇪Stockholm, Sweden